Fragile X targeted pharmacotherapy: lessons learned and future directions

Our understanding of fragile X syndrome (FXS) pathophysiology continues to improve and numerous potential drug targets have been identified. Yet, current prescribing practices are only symptom-based in order to manage difficult behaviors, as no drug to date is approved for the treatment of FXS. Drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Erickson, Craig A., Davenport, Matthew H., Schaefer, Tori L., Wink, Logan K., Pedapati, Ernest V., Sweeney, John A., Fitzpatrick, Sarah E., Brown, W. Ted, Budimirovic, Dejan, Hagerman, Randi J., Hessl, David, Kaufmann, Walter E., Berry-Kravis, Elizabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467059/
https://www.ncbi.nlm.nih.gov/pubmed/28616096
http://dx.doi.org/10.1186/s11689-017-9186-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467059/
https://www.ncbi.nlm.nih.gov/pubmed/28616096
http://dx.doi.org/10.1186/s11689-017-9186-9

Ejemplares similares